Sign in or create an account to add this stock to your watchlist.
About MannKind (NASDAQ:MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Debt
Debt-to-Equity Ratio-0.43
Current Ratio0.43
Quick Ratio0.39
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-2.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.74 million
Price / Sales23.85
Cash FlowN/A
Price / CashN/A
Book Value($1.59) per share
Price / Book-1.26
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-1,076.91%
Return on EquityN/A
Return on Assets-185.01%
Miscellaneous
Employees250
Outstanding Shares140,020,000
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) released its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The biopharmaceutical company earned $3.47 million during the quarter, compared to analyst estimates of $3.53 million. During the same quarter in the previous year, the business posted ($0.17) EPS. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
3 equities research analysts have issued 12-month price targets for MannKind's stock. Their forecasts range from $1.00 to $5.00. On average, they anticipate MannKind's stock price to reach $2.9233 in the next year. View Analyst Ratings for MannKind.
What are Wall Street analysts saying about MannKind stock?
Here are some recent quotes from research analysts about MannKind stock:
- 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (5/16/2018)
- 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)
- 3. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)
Are investors shorting MannKind?
MannKind saw a drop in short interest in April. As of April 30th, there was short interest totalling 32,530,055 shares, a drop of 9.5% from the April 13th total of 35,956,256 shares. Based on an average daily trading volume, of 2,791,129 shares, the short-interest ratio is presently 11.7 days. Currently, 27.2% of the company's stock are short sold.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Athenex (ATNX), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), Lexicon Pharmaceuticals (LXRX), Mirati Therapeutics (MRTX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Zai Lab (ZLAB), Endocyte (ECYT), Karyopharm Therapeutics (KPTI), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CytomX Therapeutics (CTMX), Amarin (AMRN) and MacroGenics (MGNX).
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 41)
- Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
- Mr. Steven B. Binder, Chief Financial Officer (Age 55)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)
Has MannKind been receiving favorable news coverage?
Media coverage about MNKD stock has been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a daily sentiment score of 0.07 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are MannKind's major shareholders?
MannKind's stock is owned by a number of of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%), BlackRock Inc. (2.62%), Scopia Capital Management LP (0.81%), Millennium Management LLC (0.74%), Tibra Equities Europe Ltd (0.20%) and Dupont Capital Management Corp (0.20%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.
Which major investors are selling MannKind stock?
Which major investors are buying MannKind stock?
MNKD stock was purchased by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Tibra Equities Europe Ltd, Element Capital Management LLC, Dupont Capital Management Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $2.00.
How big of a company is MannKind?
MannKind has a market capitalization of $280.05 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
MannKind (NASDAQ:MNKD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $2.9233, suggesting that the stock has a possible upside of 46.17%. The high price target for MNKD is $5.00 and the low price target for MNKD is $1.00. There are currently 2 sell ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.67 | 1.50 | 1.75 | 1.75 |
| Ratings Breakdown: | 2 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.9233 | $1.59 | $1.8850 | $0.9150 |
| Price Target Upside: | 46.17% upside | 49.68% downside | 28.33% downside | 71.85% downside |
MannKind (NASDAQ:MNKD) Consensus Price Target History
MannKind (NASDAQ:MNKD) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
MannKind (NASDAQ:MNKD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 17.87%
MannKind (NASDAQ MNKD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/21/2017 | Stuart A Tross | VP | Buy | 39,840 | $2.52 | $100,396.80 | 59,840 |  |
| 12/20/2017 | Michael Castagna | CEO | Buy | 8,000 | $2.29 | $18,320.00 | 35,532 | |
| 10/13/2017 | Kent Kresa | Director | Buy | 166,600 | $6.00 | $999,600.00 | | |
| 8/10/2017 | Raymond W Urbanski | CMO | Sell | 296 | $1.15 | $340.40 | 2,924 | |
| 6/30/2017 | Rosabel Realica Alinaya | SVP | Buy | 2,000 | $1.23 | $2,460.00 | 30,091 | |
| 1/3/2017 | Matthew J Pfeffer | CEO | Buy | 4,540 | $0.54 | $2,451.60 | 403,085 | |
| 1/3/2017 | Rosabel Realica Alinaya | SVP | Buy | 9,043 | $0.54 | $4,883.22 | 140,456 | |
| 8/26/2016 | Michael Castagna | Insider | Buy | 17,500 | $0.78 | $13,650.00 | 212,500 | |
| 8/24/2016 | Michael Castagna | Insider | Buy | 15,000 | $0.87 | $13,050.00 | 195,000 | |
| 8/23/2016 | Michael Castagna | Insider | Buy | 25,000 | $0.94 | $23,500.00 | 180,000 | |
| 8/15/2016 | Matthew J Pfeffer | CEO | Buy | 25,000 | $0.99 | $24,750.00 | 397,996 | |
| 8/12/2016 | Michael Castagna | Insider | Buy | 25,000 | $1.00 | $25,000.00 | 75,000 | |
| 5/17/2016 | Michael Castagna | Insider | Buy | 50,000 | $0.93 | $46,500.00 | 50,000 | |
| 4/24/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $4.83 | $354,811.80 | | |
| 3/27/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $5.21 | $382,726.60 | | |
| 2/10/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $7.75 | $569,315.00 | | |
| 2/5/2015 | David Thomson | VP | Sell | 80,000 | $7.00 | $560,000.00 | | |
| 1/5/2015 | Diane Palumbo | VP | Sell | 188,999 | $5.95 | $1,124,544.05 | | |
| 11/24/2014 | David Thomson | VP | Sell | 118,114 | $6.14 | $725,219.96 | | |
| 10/3/2014 | Juergen Martens | VP | Sell | 63,800 | $5.48 | $349,624.00 | | |
| 8/27/2014 | Juergen Martens | VP | Sell | 417 | $7.60 | $3,169.20 | | |
| 8/7/2014 | David Thomson | VP | Sell | 30,000 | $8.16 | $244,800.00 | | |
| 7/21/2014 | Juergen Martens | VP | Sell | 26,458 | $9.65 | $255,319.70 | | |
| 7/15/2014 | Diane Palumbo | VP | Sell | 17,901 | $10.01 | $179,189.01 | | |
| 7/1/2014 | Matthew J Pfeffer | CFO | Sell | 20,000 | $10.44 | $208,800.00 | | |
| 6/30/2014 | Hakan Edstrom | COO | Buy | 1,692 | $4.42 | $7,478.64 | | |
| 6/27/2014 | Juergen Martens | VP | Sell | 25,417 | $10.53 | $267,641.01 | | |
| 6/26/2014 | David Thomson | VP | Sell | 30,000 | $10.51 | $315,300.00 | | |
| 6/20/2014 | Juergen Martens | VP | Sell | 1,458 | $10.34 | $15,075.72 | | |
| 6/16/2014 | Diane Palumbo | VP | Sell | 17,902 | $10.59 | $189,582.18 | | |
| 6/5/2014 | Juergen Martens | VP | Sell | 120,000 | $11.00 | $1,320,000.00 | | |
| 6/4/2014 | David Thomson | VP | Sell | 133,000 | $9.95 | $1,323,350.00 | | |
| 6/3/2014 | Diane Palumbo | VP | Sell | 52,957 | $9.50 | $503,091.50 | | |
| 5/23/2014 | Juergen Martens | VP | Sell | 25,000 | $7.65 | $191,250.00 | | |
| 5/19/2014 | Juergen Martens | VP | Sell | 76,899 | $7.50 | $576,742.50 | 139,024 | |
| 5/15/2014 | Diane Palumbo | VP | Sell | 18,176 | $7.06 | $128,322.56 | 158,858 | |
| 1/24/2014 | Juergen Martens | VP | Sell | 50,000 | $5.56 | $278,000.00 | 139,450 | |
| 12/31/2013 | Hakan Edstrom | COO | Buy | 1,589 | $4.53 | $7,198.17 | 729,685 | |
| 12/20/2013 | Juergen Martens | VP | Sell | 32,054 | $5.00 | $160,270.00 | 139,450 | |
| 12/11/2013 | David Thomson | VP | Sell | 150,000 | $5.00 | $750,000.00 | 83,752 | |
| 11/29/2013 | Juergen Martens | VP | Sell | 48,057 | $5.01 | $240,765.57 | 171,504 | |
| 11/15/2013 | Diane Palumbo | VP | Sell | 25,000 | $5.02 | $125,500.00 | 112,756 | |
| 8/28/2013 | David Thomson | VP | Sell | 19,204 | $5.78 | $110,999.12 | 40,082 | |
| 8/26/2013 | Juergen Martens | VP | Sell | 20,000 | $5.52 | $110,400.00 | 136,016 | |
| 8/1/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $8.00 | $80,000.00 | | |
| 7/2/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $7.00 | $70,000.00 | | |
| 6/30/2013 | Diane Palumbo | VP | Buy | 1,610 | $1.96 | $3,155.60 | | |
| 6/30/2013 | Matthew J Pfeffer | CFO | Buy | 7,448 | $1.96 | $14,598.08 | | |
| 6/3/2013 | Diane Palumbo | VP | Sell | 66,849 | $7.50 | $501,367.50 | | |
| 5/16/2013 | Diane Palumbo | VP | Sell | 26,829 | $5.25 | $140,852.25 | | |
| 5/15/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $5.00 | $50,000.00 | | |
| 12/31/2012 | Matthew J Pfeffer | CFO | Buy | 1,056 | $1.95 | $2,059.20 | | |
| 12/21/2012 | Alfred E Mann | Major Shareholder | Buy | 40,000,000 | $2.59 | $103,600,000.00 | | |
(Data available from 1/1/2013 forward)
MannKind (NASDAQ MNKD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MannKind - Afrezza Scripts Crack 500, But Growth Still Slower Than Needed
seekingalpha.com - May 20 at 9:12 AM |
 | Form 4 MANNKIND CORP For: May 16 Filed by: Shannon James Samuel
www.streetinsider.com - May 18 at 5:01 PM |
 | Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro ...
globenewswire.com - May 17 at 9:14 AM |
 | Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
finance.yahoo.com - May 16 at 4:52 PM |
 | MannKind (MNKD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 16 at 3:23 PM |
| MannKind (MNKD) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM |
| Is MannKind Guidance Plausible?
seekingalpha.com - May 16 at 9:16 AM |
| MannKind Co. (MNKD) Sees Large Drop in Short Interest
www.americanbankingnews.com - May 12 at 2:10 AM |
| MannKind (MNKD) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 11 at 11:15 PM |
| MannKind - Scripts Dip, Cash, Q1 Call, And A Deal
seekingalpha.com - May 11 at 4:55 PM |
| Edited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 11 at 9:45 AM |
| MannKind's (MNKD) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - May 10 at 5:35 PM |
| Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
seekingalpha.com - May 10 at 5:02 PM |
| MannKind Inks Afrezza Deal With Cipla For India
seekingalpha.com - May 10 at 5:02 PM |
 | MannKind Q1 18 Earnings Conference Call At 5:00 PM ET
www.nasdaq.com - May 10 at 9:16 AM |
| MannKind's (MNKD) CEO Michael Castagna on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 9:16 AM |
 | MannKind Q1 Results: The Good, the Bad, and the Ugly
www.fool.com - May 10 at 6:51 AM |
 | BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India
www.reuters.com - May 9 at 4:51 PM |
| BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India
www.reuters.com - May 9 at 4:51 PM |
| MannKind Corporation Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 9 at 4:51 PM |
| MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India
finance.yahoo.com - May 9 at 9:08 AM |
| Why MannKind Corporation Stock Broke Down in April
finance.yahoo.com - May 8 at 9:02 AM |
| MannKind Earnings On Deck - What To Look For
seekingalpha.com - May 7 at 4:57 PM |
| MannKind (MNKD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 5 at 10:51 AM |
| MannKind - Afrezza Scripts Push Toward 500 As Quarterly Call Approaches
seekingalpha.com - May 5 at 9:20 AM |
| MannKind Sees Meaningful Spike In Insurance Coverage
seekingalpha.com - May 4 at 4:45 PM |
 | Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec ...
www.prnewswire.com - May 4 at 9:00 AM |
| MannKind (MNKD) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM |
| MannKind (MNKD) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 2 at 10:12 AM |
| MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 9:02 AM |
| MannKind - Afrezza Scripts Trudge Along
seekingalpha.com - April 28 at 9:24 AM |
| MannKind Co. (MNKD) Receives Consensus Rating of "Sell" from Analysts
www.americanbankingnews.com - April 28 at 1:36 AM |
| MannKind (MNKD) Confirms FDA Determined Afrezza REMS Communication Plan Has Met Goals and REMS No ...
www.streetinsider.com - April 25 at 4:54 PM |
| MannKind Gets Some Positive FDA News Regarding Afrezza
seekingalpha.com - April 25 at 9:05 AM |
| MannKind +8% as FDA clears risk hurdles for Afrezza
seekingalpha.com - April 25 at 9:05 AM |
| MannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus Far
seekingalpha.com - April 20 at 4:46 PM |
| MannKind - Afrezza Scripts Dip Back Below 500
seekingalpha.com - April 15 at 10:09 AM |
| MannKind (MNKD) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM |
 | MannKind (MNKD) Enters Oversold Territory April 13, 2018
www.zacks.com - April 13 at 9:20 AM |
| MannKind (MNKD) Enters Oversold Territory
finance.yahoo.com - April 13 at 9:20 AM |
| MannKind And Its Cash Situation
seekingalpha.com - April 11 at 4:48 PM |
| Form SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLC
www.streetinsider.com - April 9 at 4:44 PM |
| Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018
www.zacks.com - April 9 at 9:14 AM |
| Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
finance.yahoo.com - April 9 at 9:14 AM |
| Why MannKind Corporation Stock Sank Last Month
finance.yahoo.com - April 9 at 9:14 AM |
| MannKind Raises $26.7 Million In Stock Offering - Not Enough
seekingalpha.com - April 8 at 5:08 PM |
| MannKind (MNKD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:50 PM |
| MannKind Modeling And Afrezza Scripts
seekingalpha.com - April 7 at 9:30 AM |
| MannKind (MNKD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 6 at 1:55 PM |
| MannKind (MNKD) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:37 AM |
MannKind (NASDAQ:MNKD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement
MannKind (NASDAQ MNKD) Stock Chart for Monday, May, 21, 2018
Loading chart…
